The mechanisms underlying the failure to control the growth and systemic spread of
Leishmania parasites in human visceral leishmaniasis (VL) are not well understood …

Leishmaniasis is a vector-borne neglected tropical disease associated with a spectrum of
clinical manifestations, ranging from self-healing cutaneous lesions to fatal visceral …

Visceral leishmaniasis is a chronic parasitic disease associated with severe immune
dysfunction. Treatment options are limited to relatively toxic drugs, and there is no vaccine …

Kala-azar, also known as visceral leishmaniasis (VL), is a disease caused by Leishmania
infantum and L. donovani. Patients experience symptoms such as fever, weight loss …

Leishmaniasis is one of the world's important infectious diseases. It is prevalent in tropical
and subtropical regions of the world and endemic in 88 countries, with two million new …

Ninety per cent of the 500 000 annual new cases of visceral leishmaniasis (VL) occur in
India/Bangladesh/Nepal, Sudan and Brazil. Importantly, 80–90% of human infections are …

To identify susceptibility loci for visceral leishmaniasis, we undertook genome-wide
association studies in two populations: 989 cases and 1,089 controls from India and 357 …

Identifying genetic risk factors for parasitic infections such as the leishmaniases could
provide important leads for improved therapies and vaccines. Until recently most genetic …

As a whole, integral membrane proteins represent about one third of sequenced genomes,
and more than 50% of currently available drugs target membrane proteins, often cell surface …

Dogs have different susceptibility degrees to leishmaniasis; however, genetic research on
this theme is scarce, manly on visceral form. The aims of this systematic review were to …